Franklin Resources, Inc. vs Crispr Therapeutics AG — how do they compare? Franklin Resources, Inc. trades at $33.61 (market cap $16.95B), while Crispr Therapeutics AG trades at $53.78 (market cap $5.23B). The key difference: Franklin Resources, Inc. is far larger — about 3.2× Crispr Therapeutics AG's market cap, and Franklin Resources, Inc. pays a 3.96% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| BEN | CRSP | |
|---|---|---|
Market Cap | $16.95B | $5.23B |
Sector | Financials | Health |
52-Week High | $35.77 | $76.78 |
52-Week Low | $21.18 | $44.34 |
Enterprise Value | $29.90B | $3.65B |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.52, down 0.74% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $0.72, beating estimates, and achieved record AUM of $1.80 trillion as of July 31, 2026, driven by strong inflows and diversification efforts. Valuation ratios include a P/E of 22.69 and P/S of 1.85, while profitability metrics show a net income margin of 8.72%.
The outlook is positive with earnings beats and AUM growth, but risks include weaker ROE of 1.34% and net cash outflows. Analyst consensus price target is $36.50, suggesting potential upside, supported by a 'Buy' rating from 22% of analysts. Investors should monitor margin expansion and competitive pressures in the asset management sector.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Trailing returns across standard periods
Latest headlines on both assets
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →